Injection delivery system developer ApiJect announced that it promoted Molly Weaver to the position of chief operating officer.
Weaver’s background includes both the pharmaceutical and medical technology markets. Her experience spans strategy, product development and execution across a broad range of industrialization and drug delivery systems.
Most recently, Weaver served as chief technology officer at ApiJect. Responsibilities in that role included overseeing the development of the company’s Blow-Fill-Seal injection devices and production of its initial device, a single-dose, prefilled drug delivery system.
According to Weaver, the company plans to file its first FDA regulatory submission for its injector system within the next few months.
“This promotion reflects the central role Molly now plays in corporate strategy and business operations,” said Jon Ellenthal, president, ApiJect Systems. “Molly combines deep technical expertise with the business acumen, communication, and critical thinking skills needed to deliver on the full promise of our technology and team. With Molly serving as the company’s chief operating officer, ApiJect is in an even stronger position to transform how injectable medicines and vaccines are filled, finished, and delivered.”
Before ApiJect, Weaver served as VP for containment systems and portfolio management at West Pharmaceutical Services. There, she held responsibility for elastomer and container R&D, product packaging and sterilization and management of more than 30 projects across the full West portfolio. Weaver also spent time at BD and Unilife Medical Corporation.
“I am pleased with the significant progress we have made on the ApiJect Platform and excited to continue driving the transformation in injection medicine led by our company,” said Weaver.
